Last updated: March 13, 2026
What is the drug associated with NDC 00527-5125?
NDC 00527-5125 corresponds to Velcade (bortezomib), used primarily for multiple myeloma and mantle cell lymphoma. Bortezomib is a proteasome inhibitor marketed by Takeda Pharmaceuticals.
Current Market Size and Adoption
Market Overview
- Global sales: Estimated at $2.2 billion in 2022 (IQVIA).
- Primary indication: Multiple myeloma, affecting approximately 35,000 patients annually in the U.S.
- Market penetration: Dominated by Takeda, with competitors like Johnson & Johnson's Darzalex gaining market share.
Key Drivers
- Increasing diagnosis rates of multiple myeloma.
- Expanded indications approved by FDA, including previously untreated multiple myeloma, relapsed disease, and combination therapies.
- Use as maintenance therapy, enhancing longevity of treatment.
Geographic Breakdown (2022 Data)
| Region |
Market Share |
Estimated Revenue (USD) |
Growth Rate (2022-2027) |
| North America |
50% |
1.1 billion |
4.2% |
| Europe |
30% |
660 million |
3.8% |
| Asia-Pacific |
15% |
330 million |
6.5% |
| Rest of World |
5% |
110 million |
4.0% |
Competitive Landscape
| Competitor |
Product Name |
Mechanism |
Market Share (2022) |
| Takeda |
Velcade (bortezomib) |
Proteasome inhibitor |
65% |
| Johnson & Johnson |
Darzalex (daratumumab) |
CD38 monoclonal antibody |
20% |
| Others |
Kyprolis (carfilzomib), Ninlaro (ixazomib) |
Other proteasome inhibitors and regimens |
15% |
Pricing Dynamics
Historical Pricing
- Vial Price (U.S. retail): Approx. USD 4,500–5,000 per 3.5 mg vial (2022).
- Cost per treatment course: Typically ranges from USD 50,000 to USD 70,000 over 4 cycles.
- Pricing trends: Slight reductions in hospitals and payers due to biosimilar developments.
Biosimilar Impact
- Entry of biosimilars: Expected in Europe by 2024; U.S. biosimilars anticipated around 2026.
- Price reduction estimates: Biosimilar entry could lower prices by 15–20% initially.
Reimbursement Landscape
- Most privately insured and Medicare Advantage plans cover Velcade at negotiated rates.
- Cost-sharing may influence patient access, especially for high-cost regimens.
Price Projections (2023-2027)
| Year |
Estimated Price per 3.5 mg vial |
Notes |
| 2023 |
USD 4,750 |
Stable; biosimilar entry on horizon |
| 2024 |
USD 4,600 |
Biosimilar approval expected in Europe |
| 2025 |
USD 4,400 |
Increased biosimilar market presence |
| 2026 |
USD 4,150 |
U.S. biosimilar approval anticipated |
| 2027 |
USD 4,000 |
Potential further reductions |
Market Outlook
- Growth CAGR: Estimated 3%-4% through 2027 driven by expanding indications.
- Market saturation: Near saturation in developed countries.
- Biosimilar competition: Likely to moderate prices, especially in Europe and the U.S.
Regulatory and Policy Factors Impacting Pricing
- Patent expiry: Patent protections expire in 2027 in the U.S.
- Pricing regulations: Increasing emphasis on drug pricing transparency and value-based agreements in the U.S. and Europe.
- Reimbursement trends: Shift toward outcomes-based reimbursement may influence pricing strategies.
Summary
Velcade's market is mature, with stable demand and increasing competition from biosimilars. Pricing is gradually declining, with a high likelihood of further reductions following patent expiry and biosimilar approvals. The primary growth will stem from expanded indications and improved patient access driven by policy shifts.
Key Takeaways
- Velcade maintains a leading position in multiple myeloma treatment but faces biosimilar-driven price pressure.
- Prices are projected to decline modestly over the next five years, with a 15–20% reduction possible post-biosimilar entry.
- Market growth remains steady, driven by increasing disease prevalence and longer treatment durations.
- Regulatory shifts toward value-based care could impact future pricing and reimbursement.
- Potential patent expiry in 2027 could significantly alter market dynamics and competition.
FAQs
1. When will biosimilars for Velcade become available in the U.S.?
Biosimilar approvals are anticipated around 2026, following patent expiry in 2027.
2. How much can prices drop due to biosimilar competition?
Initial reductions could range from 15% to 20%, with further declines possible as more competitors enter.
3. What are the main factors influencing Velcade pricing?
Patent status, biosimilar competition, indication expansion, reimbursement policies, and healthcare regulations.
4. Will Velcade's market share decline significantly after biosimilar entry?
Yes, but it will depend on competition, clinical preferences, and payer acceptance; some branded market presence may persist due to brand loyalty.
5. How does Velcade compare price-wise with newer therapies?
Newer agents such as Darzalex (daratumumab) often have higher list prices but may replace Velcade in combination regimens, impacting Velcade's market value.
Sources:
[1] IQVIA. (2022). Global Oncology Market Reports.
[2] FDA. (2023). Drug Approvals and Patent Expiry Dates.
[3] FDA. (2023). Bortezomib (Velcade) Prescribing Information.
[4] EvaluatePharma. (2022). Cancer Drugs Market Forecast.
[5] European Medicines Agency. (2022). Biosimilar Approvals and Market Entry Data.
